Head-To-Head Analysis: Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) & Medtronic (NYSE:MDT)

Medtronic (NYSE:MDT) and Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Medtronic and Senseonics Holdings, Inc. Common Stock”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medtronic	$37.54 billion	3.25	$4.80 billion	$4.06	23.52
Senseonics Holdings, Inc. Common Stock	$35.26 million	8.90	-$69.11 million	($2.23)	-3.37

Medtronic has higher revenue and earnings than Senseonics Holdings, Inc. Common Stock. Senseonics Holdings, Inc. Common Stock is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.1% of Medtronic shares are held by institutional investors. Comparatively, 12.4% of Senseonics Holdings, Inc. Common Stock shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Comparatively, 4.7% of Senseonics Holdings, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Medtronic and Senseonics Holdings, Inc. Common Stock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medtronic	13.93%	14.78%	7.97%
Senseonics Holdings, Inc. Common Stock	-225.09%	-165.80%	-80.14%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Medtronic and Senseonics Holdings, Inc. Common Stock, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medtronic	1	9	18	0	2.61
Senseonics Holdings, Inc. Common Stock	1	2	3	0	2.33

Medtronic presently has a consensus price target of $102.88, indicating a potential upside of 7.75%. Senseonics Holdings, Inc. Common Stock has a consensus price target of $13.00, indicating a potential upside of 73.10%. Given Senseonics Holdings, Inc. Common Stock’s higher possible upside, analysts clearly believe Senseonics Holdings, Inc. Common Stock is more favorable than Medtronic.

Risk & Volatility

Medtronic has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Senseonics Holdings, Inc. Common Stock has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Summary

Medtronic beats Senseonics Holdings, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company’s products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.